• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed

    2/12/21 4:31:19 PM ET
    $TRXC
    Medical/Dental Instruments
    Health Care
    Get the next $TRXC alert in real time by email
    transe20210211_8k.htm
    false 0000876378 0000876378 2021-02-08 2021-02-08
     


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549
    _________________
     
    FORM 8-K
    _________________
     
    CURRENT REPORT
     
    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934
     
    February 8, 2021
    Date of Report (date of earliest event reported)
    _________________
     
    TransEnterix, Inc.
    (Exact name of Registrant as specified in its charter)
    _________________
     
    Delaware
    (State or other jurisdiction of incorporation or organization)
     
    0-19437
    (Commission
    File Number)
     
    11-2962080
    (I.R.S. Employer
    Identification Number)
     
    635 Davis Drive, Suite 300
    Morrisville, North Carolina 27560
    (Address of principal executive offices)
     
    919-765-8400
    (Registrant’s telephone number, including area code)
     
    Not Applicable
    (Former name or former address, if changed since last report)
    _________________
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
    ☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
     
    Trading symbol
     
    Name of each exchange on which registered
    Common Stock
    $0.001 par value per share
     
    TRXC
     
    NYSE American
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       ☐
     


     
     

     
     
    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     
    On February 8, 2021, the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of TransEnterix, Inc. (the “Company”) approved the 2020 incentive bonus, retention bonuses and compensation changes for 2021 for the executive officers of the Company. Such approved compensation for Anthony Fernando, the Company’s President and Chief Executive Officer, was recommended to, and approved by, the independent directors of the full Board.
     
    As will be described in more detail in the Company’s proxy materials for its 2021 Annual Meeting of Stockholders to be held later this year, the 2020 bonus was based on achievement of the pre-established corporate goals at a 64% achievement rate. The CEO’s base salary was not adjusted for 2021, the base salary for the Chief Financial Officer was increased in accordance with his employment offer letter in August 2020. The 2021 equity awards, consist of a one-third mix each of stock options, time-based restricted stock units (with a three-year vesting schedule) and performance-based restricted stock units (with a three-year vesting that occurs only upon achievement of a designated corporate performance goal).
     
    In addition, the Committee and the independent members of the Board approved one-time discretionary retention bonuses consisting of cash and RSUs with a one-year cliff vesting period for the CEO and CFO as set forth below. The executive officers filed the required Form 4 reports related to the equity awards granted.
     
    These annual and one-time awards were made after careful consideration of the extraordinary efforts of the executive officers, particularly Mr. Fernando, in leading the Company through the challenges of 2020 and 2021 to date, achieving success in the reaching the pre-established corporate goals at a 64% level of achievement despite such challenges, and maintaining the Company’s focus on its strategic goals while securing financing for the Company expected to extend its cash reach into 2024, and adapting to the impact of COVID-19 on the Company’s business and strategic focus. The Committee also considered the executive officers’ compensation as compared to the peer company executive compensation data for the Company’s peer group of companies in making these awards. Following these awards the executive officers collectively hold shares and equity awards equal to approximately 2.0% of outstanding shares.
     
    2021 Equity Grants to Executive Officers
     
    Executive Officer
    Stock Options
    RSUs
    PRSUs
    Anthony Fernando, President and Chief Executive Officer
    868,161
    702,256
    702,256
    Shameze Rampertab, EVP and Chief Financial Officer
    73,078
    59,112
    59,112
     
    2021 Discretionary Retention Bonus
     
    Executive Officer
    RSUs
    Cash
     
    Anthony Fernando, President and Chief Executive Officer
    295,900
    $500,000
     
    Shameze Rampertab, EVP and Chief Financial Officer
    59,200
    $50,000
     

    Forward-Looking Statements
     
    This Current Report on Form 8-K includes statements relating the anticipated cash reach of the Company. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include market and other conditions, and whether it will be successfully completed, For a discussion of the risks and uncertainties associated with our business, please review our filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     
    TRANSENTERIX, INC.
    Date: February 12, 2021 
     
    /s/ Shameze Rampertab
    Shameze Rampertab
    Executive Vice President and Chief Financial Officer
     
     
     
    Get the next $TRXC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TRXC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TRXC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Asensus Surgical, Inc. Schedules Fourth Quarter and Fiscal Year 2020 Financial and Operating Results Conference Call for March 11, 2021

    RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (NYSE American: TRXC) (formerly TransEnterix, Inc.), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced today that it plans to release fourth quarter and fiscal year 2020 financial and operating results after the market closes on Thursday, March 11, 2021. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-855-327-6837 for domestic callers and 1-631-891-4304

    3/4/21 6:55:00 AM ET
    $TRXC
    Medical/Dental Instruments
    Health Care

    Asensus Surgical Announces FDA Clearance in General Surgery

    RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (formerly TransEnterix, Inc.) (NYSE American: TRXC) , a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, today announced the Company has received an additional FDA clearance for the Senhance Surgical System which allows for indication expansion in general surgery in the United States. Asensus Surgical's technology platform, Senhance® Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning.

    3/3/21 6:55:00 AM ET
    $TRXC
    Medical/Dental Instruments
    Health Care

    Asensus Surgical to Present at the H.C. Wainwright Virtual Global Life Sciences Conference

    RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (NYSE American: TRXC) (formerly TransEnterix, Inc.), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery, announced today that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the H.C. Wainwright Virtual Global Life Sciences Conference taking place March 9 and March 10, 2021. The Company’s presentation will be available for on-demand beginning Tuesday, March 9, 2021 at 7:00 am ET. The on-demand conference presentation wil

    3/1/21 6:55:00 AM ET
    $TRXC
    Medical/Dental Instruments
    Health Care

    $TRXC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Rampertab Shameze

    4 - TRANSENTERIX, INC. (0000876378) (Issuer)

    2/8/21 8:50:49 PM ET
    $TRXC
    Medical/Dental Instruments
    Health Care

    SEC Form 4: J. C. Anthony Fernando exercised 146,873 units of Common Stock at a strike of $0.00 and disposed of $214,521 worth of Common Stock (67,248 units at $3.19), increasing ownership by 143% to 135,126 units

    4 - TRANSENTERIX, INC. (0000876378) (Issuer)

    2/8/21 8:48:15 PM ET
    $TRXC
    Medical/Dental Instruments
    Health Care

    $TRXC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - TRANSENTERIX, INC. (0000876378) (Subject)

    2/16/21 9:51:05 AM ET
    $TRXC
    Medical/Dental Instruments
    Health Care

    $TRXC
    SEC Filings

    View All

    SEC Form 8-K filed

    8-K - ASENSUS SURGICAL, INC. (0000876378) (Filer)

    3/12/21 4:31:17 PM ET
    $TRXC
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed

    10-K - ASENSUS SURGICAL, INC. (0000876378) (Filer)

    3/11/21 5:22:06 PM ET
    $TRXC
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed

    8-K - ASENSUS SURGICAL, INC. (0000876378) (Filer)

    3/3/21 4:31:01 PM ET
    $TRXC
    Medical/Dental Instruments
    Health Care